Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

7.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.9K
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

687
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
687
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

720
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
720
Mechanistic Models: Overview of Compartment Models01:21

Mechanistic Models: Overview of Compartment Models

83
Mechanistic models, a category encompassing both physiological and compartmental modeling, differ from empirical models' approaches to incorporating known factors about the systems being modeled. Empirical models describe data with minimal assumptions, while mechanistic models aim to provide a robust description of available data by specifying assumptions and integrating known factors about the system. Compartmental analysis is a key example of a mechanistic model in pharmacokinetics and...
83
Molecular Models02:00

Molecular Models

38.3K
Physical models representing molecular architectures of chemical compounds play essential roles in understanding chemistry. The use of molecular models makes it easier to visualize the structures and shapes of atoms and molecules.
38.3K
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

69
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
69

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TURBO-RL: turbulence mitigation using reinforcement learning for severe optical aberrations.

Journal of the Optical Society of America. A, Optics, image science, and vision·2026
Same author

Alz-QNet: A quantum regression network for studying Alzheimer's gene interactions.

Computers in biology and medicine·2025
Same author

Modeling Brain Aging With Explainable Triamese ViT: Towards Deeper Insights Into Autism Disorder.

IEEE journal of biomedical and health informatics·2025
Same author

Improving Molecule Generation and Drug Discovery With a Knowledge-Enhanced Generative Model.

IEEE transactions on computational biology and bioinformatics·2024
Same author

Understanding the natural language of DNA using encoder-decoder foundation models with byte-level precision.

Bioinformatics advances·2024
Same author

Understanding the Natural Language of DNA using Encoder-Decoder Foundation Models with Byte-level Precision.

ArXiv·2024
Same journal

Poisoning the Genome: Targeted Backdoor Attacks on DNA Foundation Models.

ArXiv·2026
Same journal

Mechanistic mathematical model of the in vitro infection dynamics of Bunyamwera and Batai viruses including MOI-dependent shortening of the eclipse phase.

ArXiv·2026
Same journal

AI-Driven Lumped-Element Modeling of Human Respiratory System for Studying Voice Mechanics.

ArXiv·2026
Same journal

Beyond Algorithms: Conceptual Innovation in Medical Imaging AI.

ArXiv·2026
Same journal

Feynman Kac Reweighted Schrödinger Bridge Matching for Surface-Based Tau PET Harmonization.

ArXiv·2026
Same journal

Agentic Discovery of Non-Canonical Antimicrobial Peptides with AMPGAN v3.

ArXiv·2026
See all related articles

Related Experiment Video

Updated: Jul 2, 2025

Curation of Computational Chemical Libraries Demonstrated with Alpha-Amino Acids
08:21

Curation of Computational Chemical Libraries Demonstrated with Alpha-Amino Acids

Published on: April 13, 2022

2.6K

Improving Molecule Generation and Drug Discovery with a Knowledge-enhanced Generative Model.

Aditya Malusare1, Vaneet Aggarwal1

  • 1Edwardson School of Industrial Engineering and the Institute of Cancer Research, Purdue University.

Arxiv
|February 27, 2024
PubMed
Summary
This summary is machine-generated.

We developed KARL, a knowledge-enhanced generative model framework, to integrate biomedical knowledge graphs with generative models for drug discovery. KARL effectively generates valid and synthesizable novel drug candidates, outperforming existing methods.

More Related Videos

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.6K
Modeling an Enzyme Active Site using Molecular Visualization Freeware
14:37

Modeling an Enzyme Active Site using Molecular Visualization Freeware

Published on: December 25, 2021

9.8K

Related Experiment Videos

Last Updated: Jul 2, 2025

Curation of Computational Chemical Libraries Demonstrated with Alpha-Amino Acids
08:21

Curation of Computational Chemical Libraries Demonstrated with Alpha-Amino Acids

Published on: April 13, 2022

2.6K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.6K
Modeling an Enzyme Active Site using Molecular Visualization Freeware
14:37

Modeling an Enzyme Active Site using Molecular Visualization Freeware

Published on: December 25, 2021

9.8K

Area of Science:

  • Artificial Intelligence
  • Cheminformatics
  • Drug Discovery

Background:

  • Generative models achieve state-of-the-art results in molecule generation.
  • A gap exists in leveraging biomedical knowledge graphs to enhance generative drug discovery models.

Purpose of the Study:

  • To bridge the gap between generative models and biomedical knowledge graphs.
  • To introduce KARL, a novel framework for knowledge-enhanced generative models.

Main Methods:

  • Developed a scalable methodology to extend knowledge graphs while preserving semantic integrity.
  • Integrated knowledge graph embeddings into a diffusion-based generative model.
  • Guided the generative process using contextual biomedical information.

Main Results:

  • KARL successfully generates novel drug candidates with specific characteristics.
  • Ensured the validity and synthesizability of generated molecules.
  • KARL demonstrated superior performance on both unconditional and targeted generation tasks compared to state-of-the-art models.

Conclusions:

  • KARL represents a significant advancement in knowledge-enhanced generative drug discovery.
  • The framework effectively integrates biomedical knowledge to improve the generation of drug candidates.
  • This approach holds promise for accelerating the discovery of novel therapeutics.